The short version
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Ibuprofen and famotidine · IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 · Tablet, Film Coated · Oral · Asclemed USA, Inc.
NDC 76420-0891-01 · 100 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 67877-0626-90) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Advanced Rx of Tennessee, LLC | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Ascend Laboratories, LLC | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Asclemed USA, Inc. | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Doc Rx | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Preferred Pharmaceuticals Inc. | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Remedyrepack Inc. | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Phoenix Rx Llc | IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 | Aug 26, 2026 | Aug 31, 2026 |
| Phoenix Rx Llc | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 21, 2026 |
| Advanced Rx of Tennessee, LLC | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Ascend Laboratories, LLC | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Asclemed USA, Inc. | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Aurobindo Pharma Limited | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Bryant Ranch Prepack | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Doc Rx | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Preferred Pharmaceuticals Inc. | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Remedyrepack Inc. | IBUPROFEN 26.6 mg/1; FAMOTIDINE 800 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Phoenix Rx Llc | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| Advanced Rx of Tennessee, LLC | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Ascend Laboratories, LLC | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Asclemed USA, Inc. | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Aurobindo Pharma Limited | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Bryant Ranch Prepack | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Doc Rx | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Preferred Pharmaceuticals Inc. | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Remedyrepack Inc. | FAMOTIDINE 26.6 mg/1; IBUPROFEN 800 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Ibuprofen and famotidine — NDC 76420-0891-01," retrieved September 3, 2026, https://drugdashboards.com/drug/76420089101.
Free to cite with attribution — see how the data is put together.